Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.62 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.62 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983314 | 0.92 | MKNK1 (0.55) | MKNK1MKNK2RIPK1HPGDDPP4 | |
| SCHEMBL31428757 | 0.89 | RIPK1 (0.59) | MKNK1MKNK2RIPK1HPGDPKM | |
| SCHEMBL31428833 | 0.88 | CCR3 (0.66) | MKNK1MKNK2CCR3 | |
| SCHEMBL6986208 | 0.86 | HPGD (0.71) | RIPK1HPGDDPP4DPP8ALOX15 | |
| SCHEMBL28256059 | 0.85 | HPGD (0.57) | MKNK1MKNK2HPGDDPP4DPP8 | |
| SCHEMBL3296940 | 0.84 | HPGD (0.56) | MKNK1MKNK2HPGDDPP4DPP8 | |
| SCHEMBL31428565 | 0.84 | RIPK1 (0.60) | MKNK1MKNK2RIPK1HPGDDPP4 | |
| SCHEMBL31428919 | 0.83 | CCR3 (0.55) | MKNK1MKNK2HPGDDPP4DPP8 | |
| SCHEMBL31428718 | 0.83 | HPGD (0.55) | MKNK1MKNK2HPGDDPP4DPP8 | |
| SCHEMBL28178640 | 0.82 | SMN1; SMN2 (0.63) | MKNK1MKNK2RIPK1HPGDDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-0991624-B1 | PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-6300342-B1 | FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION | BOEHRINGER INGELHEIM PHARM KG (DE) | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | MKNK1 511/4885MKNK2 785/4885RIPK1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.